Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

  1. Home
  2. /Regulatory
  3. /Fda Advisory Committee

Regulatory Event

FDA Advisory Committee

FDA advisory committee meetings and votes that shape approval decisions, label language, and post-market requirements.

Recent events
0
Catalysts
2
Companies
2

Recent events

No signals indexed for this entity yet.

Historical activity(2)

Advisory Committee

Sarepta Therapeutics — Elevidys

AdCom on broader ambulatory use carries high stakes for gene therapy revenue trajectory.

July 18, 2026 · Approved

Advisory Committee

Eli Lilly — Donanemab

AdCom outcome will signal FDA tolerance for amyloid-lowering therapies in broader populations.

July 8, 2026 · NDA/BLA

Related companies

Eli Lilly →
Sarepta Therapeutics →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.